InsiderTrades

Form 4 for IBRX ImmunityBio, Inc.

Accepted 2025-01-03 00:00:00 ET · period of report 2024-12-31 · accession 0001326110-25-000003 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2025-01-03 2024-12-31 IBRX Sachs David C. CFO M - OptEx $0.00 +30.4K 216.2K +16% $0
D 2025-01-03 2024-12-31 IBRX Sachs David C. CFO F - Tax $2.56 -15.4K 200.8K -7% -$39.4K
D 2025-01-03 2024-12-31 IBRX Sachs David C. CFO M - OptEx $0.00 -30.4K 76.0K -29% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-12-31 M A 30,397 $0.00 216,235 D — —
2 Common Common Stock 2024-12-31 F D 15,405 $2.56 200,830 D — —
3 Derivative Restricted Stock Units 2024-12-31 M D 30,397 $0.00 75,999 D — · — to — 30,397 Common Stock (F1) Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock. (F2) 17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.